Rubella virus vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rubella virus vaccine
Accession Number
DB10317
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Synonyms
  • Rubella virus (vaccine strain ra27/3) live antigen
  • Rubella virus live antigen, A
  • Rubella virus strain wistar ra 27/3 live (attenuated) antigen
  • Rubella virus strain wistar ra 27/3 live antigen
  • Rubella virus vaccine live (wistar ra 27-3 strain)
  • Rubella virus vaccine,live
  • Rubella, live attenuated
  • Rubivirus rubella virus wistar ra 27/3 whole
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
M-M-R IIRubella virus vaccine (1000 TCID50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 TCID50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUs
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUs
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30Us
PriorixRubella virus vaccine (103.0 CCID50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (103.0 CCID50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (103.7 CCID50/0.5mL)Kit; Powder, for solutionIntramuscular; SubcutaneousGlaxosmithkline Inc1998-12-04Not applicableCanada
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.2015-07-01Not applicableUs
ProQuadRubella virus vaccine (3 log10 tcid50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (3 log10 tcid50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (3.99 log10 tcid50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.2014-05-09Not applicableCanada
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Limited2005-09-062018-08-31Us
International/Other Brands
Meruvax II
Categories
UNII
52202H034Z
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with 2-Methoxyethanol.
2-MethoxyethanolThe risk or severity of infection can be increased when Rubella virus vaccine is combined with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Rubella virus vaccine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abatacept.
AbataceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
AbetimusThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abetimus.
AbetimusThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910496
ATC Codes
J07BJ01 — Rubella, live attenuated

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionMumps / Rubella / Rubeola2
3RecruitingPreventionHealthy Volunteers (Meningococcal Infection)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionSubcutaneous
Powder, for solutionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on November 02, 2018 07:03